全文获取类型
收费全文 | 5663篇 |
免费 | 327篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 169篇 |
妇产科学 | 124篇 |
基础医学 | 851篇 |
口腔科学 | 31篇 |
临床医学 | 501篇 |
内科学 | 1435篇 |
皮肤病学 | 112篇 |
神经病学 | 713篇 |
特种医学 | 110篇 |
外科学 | 405篇 |
综合类 | 10篇 |
一般理论 | 1篇 |
预防医学 | 293篇 |
眼科学 | 46篇 |
药学 | 448篇 |
中国医学 | 13篇 |
肿瘤学 | 739篇 |
出版年
2024年 | 1篇 |
2023年 | 37篇 |
2022年 | 102篇 |
2021年 | 141篇 |
2020年 | 85篇 |
2019年 | 115篇 |
2018年 | 132篇 |
2017年 | 114篇 |
2016年 | 139篇 |
2015年 | 156篇 |
2014年 | 197篇 |
2013年 | 260篇 |
2012年 | 413篇 |
2011年 | 435篇 |
2010年 | 255篇 |
2009年 | 233篇 |
2008年 | 401篇 |
2007年 | 387篇 |
2006年 | 387篇 |
2005年 | 387篇 |
2004年 | 392篇 |
2003年 | 321篇 |
2002年 | 289篇 |
2001年 | 49篇 |
2000年 | 37篇 |
1999年 | 55篇 |
1998年 | 77篇 |
1997年 | 65篇 |
1996年 | 52篇 |
1995年 | 50篇 |
1994年 | 42篇 |
1993年 | 37篇 |
1992年 | 24篇 |
1991年 | 29篇 |
1990年 | 21篇 |
1989年 | 18篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 13篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 10篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有6033条查询结果,搜索用时 31 毫秒
111.
Silvia Udali Annalisa Castagna Michela Corbella Andrea Ruzzenente Sara Moruzzi Filippo Mazzi Tommaso Campagnaro Domenica De Santis Antonia Franceschi Patrizia Pattini Rossella Gottardo Oliviero Olivieri Luigi Perbellini Alfredo Guglielmi Sang‐Woon Choi Domenico Girelli Simonetta Friso 《European journal of clinical investigation》2018,48(2)
112.
Jessica C Fanzo Matthew M Graziose Klaus Kraemer Stuart Gillespie Jessica L Johnston Saskia de Pee Eva Monterrosa Jane Badham Martin W Bloem Alan D Dangour Richard Deckelbaum Achim Dobermann Patrizia Fracassi SM Moazzem Hossain John Ingram Johann C Jerling CJ Jones Stefanus Indrayana Jap Lynnda Kiess Quinn Marshall Keith Martin Anuradha Narayan Mary Amuyunzu-Nayamongo Fré Pepping Keith P West 《Advances in nutrition (Bethesda, Md.)》2015,6(6):639-647
Nearly all countries in the world today are burdened with malnutrition, manifesting as undernutrition, micronutrient deficiencies, and/or overweight and obesity. Despite some progress, efforts to alleviate malnutrition are hampered by a shortage in number, skills, and geographic coverage, of a workforce for nutrition. Here, we report the findings of the Castel Gandolfo workshop, a convening of experts from diverse fields in March 2014 to consider how to develop the capacity of a global cadre of nutrition professionals for the post-2015 development era. Workshop participants identified several requirements for developing a workforce for nutrition, including an ability to work as part of a multisectoral team; communication, advocacy, and leadership skills to engage decision makers; and a set of technical skills to address future challenges for nutrition. Other opportunities were highlighted that could immediately contribute to capacity development, including the creation of a consortium to link global North and South universities, online training modules for middle managers, and practical, hands-on experiences for frontline nutrition workers. Institutional and organizational support is needed to enable workshop recommendations on education and training to be effectively implemented and sustained. The findings from the Castel Gandolfo workshop can contribute to the delivery of successful nutrition-relevant actions in the face of mounting external pressures and informing and attaining the forthcoming Sustainable Development Goals. 相似文献
113.
Pasquale Vergara MD PhD Carlo Pignalberi MD Ennio C. Pisanò MD Giampiero Maglia MD Paolo Della Bella MD Gabriele Zanotto MD Saverio Iacopino MD Francesco Solimene MD Valeria Calvi MD Massimiliano Marini MD Massimo Giammaria MD Mauro Biffi MD Giovanni Rovaris MD Fabrizio Caravati MD Fabio Quartieri MD Antonio Curnis MD Antonio Rapacciuolo MD PhD Gaetano Senatore MD Stefano Pedretti MD Davide Saporito MD Antonio Dello Russo MD Vincenzo E. Santobuono MD PhD Patrizia Pepi MD Antonio Duca MD Matteo Baroni MD Giulio Falasconi MD Daniele Giacopelli MSc Alessio Gargaro MSc Antonio D'Onofrio MD 《Journal of cardiovascular electrophysiology》2021,32(9):2528-2535
114.
D'Angelo A Della Valle P Crippa L Fattorini A Pattarini E Viganò D'Angelo S 《Haematologica》2002,87(10):1074-1080
BACKGROUND AND OBJECTIVES: In vitro studies have shown that the rate of prothrombin activation is linearly related to the concentration of factor II (FII) in the assay system, suggesting a key role of prothrombin levels in the expression of the antithrombotic activity of oral anticoagulant treatment (OAT). We investigated the in vivo relationship between prothrombin activation and vitamin K-dependent clotting factor levels during the early and steady phases of OAT in patients and in healthy volunteers. DESIGN AND METHODS: The changes in international normalizezd ratio (INR) and in the plasma levels of FVII, FX, FII, protein C (PC) and prothrombin fragment 1.2 (F1+2) induced by OAT were monitored over 9 days in 10 patients not on heparin starting warfarin after heart valve replacement (HVR) and in 9 healthy volunteers submitted to an 8-day course of warfarin treatment. FII and F1+2 plasma levels were also measured in 100 patients on stable oral anticoagulant treatment with INRs ranging from 1.2 to 6.84. RESULTS: Because HVR patients had subnormal FVII, FX and FII levels after surgery, INR values > 2.0 were attained already 24 hours after the first warfarin dose. In healthy volunteers, INR values greater than 2.0 were first observed after 72 hours. Nadir levels of FVII, PC, FX and FII were reached between 40 and 88 hours in HVR patients and between 72 and 192 hours in healthy volunteers. The FII apparent half-disappearance time (t/2) was 99 hours in HVR patients and 115 hours in healthy volunteers (p = ns). In HVR patients there was no normalization of initially elevated F1+2 levels until day 7 with an apparent t/2 of 132 hours. In healthy volunteers, a decrease to subnormal F1+2 levels was observed by day 8 of treatment (apparent t/2 = 107 hours). In both HVR patients and healthy volunteers, FII and PC levels were independent predictors of the changes in F1+2 levels (p = 0.0001). In patients on stable OAT, only FII levels were independent predictors of the variation in F1+2 levels (p = 0.0001). INTERPRETATION AND CONCLUSIONS: During the early phase of oral anticoagulant treatment in vivo prothrombin activation is a function of the balance between FII and PC levels and is not significantly prevented until nadir levels of FII are obtained. This provides an explanation for the requirement of overlapping heparin and oral anticoagulant treatment for at least 48 hours after the achievement of therapeutic INR values in patients with thromboembolic diseases. In addition, in vivo prothrombin activation is a function of FII levels rather than INR values also in patients on stable oral anticoagulant treatment. 相似文献
115.
Genetic Mapping and Tailored Antihypertensive Therapy 总被引:1,自引:0,他引:1
Ferrari P Bianchi G 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2000,14(4):387-395
A tailored or individualized antihypertensive therapy represents the new frontier for the treatment of essential hypertension and its organ complications. Indeed, individual variation in the efficacy and tolerability of antihypertensive drugs in human essential hypertension is currently experienced by all physicians and is linked to the genetic heterogeneity of this multifactorial disease. Different approaches have been pursued in the attempt to correlate specific responsiveness to the therapy with phenotypic traits of the patients, but with poor results. More recently, the genetic approach to the study of the mechanisms underlying hypertension has led to the identification of some quantitative trait loci or genes that influence blood pressure both in animal models and in patients.But the relevance of these polymorphisms for defining and classifying patients in terms of therapy responsiveness must be analyzed in a more complex context that takes into account the crucial aspects of environmental influences, stage of disease, previous treatments, efficacy, tolerance, and duration of the treatment. Only a few examples of a pharmacogenomic approach to hypertension therapy are now available. In particular, the association of different variants of ACE, angiotensinogen, and G-protein genes with the blood pressure response to drugs interfering with RAS or -adrenergic receptor has been studied. However, the results of these studies cannot be considered conclusive, since not all the criteria have been fully applied for proper assessment of an association between genetic polymorphism and drug response. Our group has identified a polymorphism of the genes coding for the cytoskeletal protein, adducin, which is associated with both rat and human hypertension, sodium sensitivity, and the antihypertensive effects of diuretics. A modification of the renal Na–KATPase leading to an increase of tubular sodium reabsorption seems to be the most likely underlying mechanism. A new antihypertensive compound has been developed that can correct the abnormality of the renal Na–KATPase and the blood pressure increase associated with adducin polymorphism in the rat. At present, the antihypertensive activity of this compound is under evaluation in patients with different adducin genotypes. 相似文献
116.
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? 总被引:4,自引:0,他引:4
Cillo U Bassanello M Vitale A Grigoletto FA Burra P Fagiuoli S D'Amico F Ciarleglio FA Boccagni P Brolese A Zanus G D'Amico DF 《Journal of hepatology》2004,40(1):124-131
BACKGROUND/AIMS: Prognosis assessment in patients with hepatocellular carcinoma (HCC) remains controversial. The most widely used HCC prognostic tool is the Okuda classification, but new staging systems (Cancer of the Liver Italian Program score, Chinese University Prognostic Index, French classification and Barcelona Clinic Liver Cancer, BCLC, staging) have been recently described. We investigated the value of known prognostic systems in the particular setting of a surgically oriented Liver Unit where 187 HCC Italian patients were mainly treated with radical therapies (resection and percutaneous ablation). METHODS: A retrospective analysis of 187 HCCs observed at a single Institution from 1990 and 1999 was performed. By using survival time as the only outcome measure (Kaplan-Meier method and Cox regression), the performance of any prognostic system was assessed according the criteria of discriminatory and stratification abilities between different stages, homogeneity of survival within each stage and additional explanatory power respect to the other classifications. RESULTS: In the particular cohort studied, BCLC proved the best HCC prognostic system. This was true for the whole study group and for the 2 subgroups of surgical and non-surgical patients. CONCLUSIONS: BCLC staging showed the best interpretation of the survival distribution in an HCC population comprising a large proportion of tumors treated with potentially radical therapies. 相似文献
117.
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein 总被引:13,自引:0,他引:13
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
118.
119.
Patrizia Noris Eloisa Arbustini Pierangelo Spedini Simona Belletti & Carlo Luigi Balduini 《British journal of haematology》1998,103(4):1004-1013
We describe a new variant of Bernard-Soulier syndrome characterized by almost normal amounts of GPIb and severely reduced GPIX and GPV. Despite surface expression, GPIbα failed to support ristocetin-induced platelet agglutination and to bind two conformation-dependent monoclonal antibodies, suggesting a qualitative defect. Sequence analysis of the gene coding for GPIX revealed a T-to-C substitution at base 1811, leading to a Leu40Pro conversion, whereas no defects were found in the coding region of the GPIbα gene. Allele-specific restriction enzyme analysis showed that the propositus and one of his sisters, both with severe bleeding diathesis, were homozygous for the GPIX mutation; the members of the family with mild bleeding diathesis and/or giant platelets in the peripheral blood were heterozygous, whereas the healthy ones were homozygous for the normal allele.
Infusion of 1-desamino-8- d -arginine vasopressin normalized bleeding time in the two severely affected patients, although it did not modify ristocetin-induced platelet agglutination or membrane expression of GPIbα, GPIX, GPIIb–IIIa and GMP-140. Moreover, in one patient, normalization of bleeding time and rise of von Willebrand factor plasma concentration did not seem to be directly related. 相似文献
Infusion of 1-desamino-8- d -arginine vasopressin normalized bleeding time in the two severely affected patients, although it did not modify ristocetin-induced platelet agglutination or membrane expression of GPIbα, GPIX, GPIIb–IIIa and GMP-140. Moreover, in one patient, normalization of bleeding time and rise of von Willebrand factor plasma concentration did not seem to be directly related. 相似文献
120.
Addolorata Carcagnì Patrizia Presbitero 《Catheterization and cardiovascular interventions》2004,62(3):409-414
Anatomical atrial septal defect (ASD) diameter measured by transesophageal echocardiography (TEE) underestimates the Amplatzer septal occluder (ASO) size for ASD closure. The aim of this study is to investigate whether a new echocardiographic diameter (procedural ASD diameter) may enable precise measurements of ASO device size. Fifty adult patients with secundum ASD were evaluated by TEE for percutaneous closure. The procedural ASD diameter was measured using the steadier rim borders where thickness was 2.5 mm. Out of the 50 patients, 12 were considered unsuitable for Amplatzer device closure. The other 38 patients underwent percutaneous closure. The mean anatomical ASD diameter was 14.8 +/- 7.0 mm, the mean procedural ASD diameter measured 19.5 +/- 8.1 mm, and the mean stretched balloon diameter (SBD) was 20.0 +/- 8.0 mm. ASO device size was 20.1 +/- 8.0 mm. At linear regression analysis, a high correlation (r = 0.99) was found between procedural ASD diameter and SBD. Procedural ASD diameter correlates with SBD and may allow reliable prediction of Amplatzer device in an adult population undergoing percutaneous ASD closure. 相似文献